<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="psp413023" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10583237</article-id><article-id pub-id-type="pmcid-ver">PMC10583237.1</article-id><article-id pub-id-type="pmcaid">10583237</article-id><article-id pub-id-type="pmcaiid">10583237</article-id><article-id pub-id-type="pmid">37667529</article-id><article-id pub-id-type="doi">10.1002/psp4.13023</article-id><article-id pub-id-type="publisher-id">PSP413023</article-id><article-id pub-id-type="other">PSP-2023-0084</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Physiologically&#8208;based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B</article-title><alt-title alt-title-type="right-running-head">PBPK Modeling of Simeprevir as a Perpetrator</alt-title><alt-title alt-title-type="left-running-head">Nakayama et al.</alt-title></title-group><contrib-group><contrib id="psp413023-cr-0001" contrib-type="author"><name name-style="western"><surname>Nakayama</surname><given-names initials="S">Shinji</given-names></name><xref rid="psp413023-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413023-cr-0002" contrib-type="author"><name name-style="western"><surname>Toshimoto</surname><given-names initials="K">Kota</given-names></name><xref rid="psp413023-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="psp413023-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="psp413023-cr-0003" contrib-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names initials="S">Shinji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7112-2812</contrib-id><xref rid="psp413023-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="psp413023-cr-0004" contrib-type="author"><name name-style="western"><surname>Snoeys</surname><given-names initials="J">Jan</given-names></name><xref rid="psp413023-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="psp413023-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Sugiyama</surname><given-names initials="Y">Yuichi</given-names></name><xref rid="psp413023-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="psp413023-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><address><email>y-sugiyama@jiu.ac.jp</email></address></contrib></contrib-group><aff id="psp413023-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">DMPK Research Laboratories, Shoyaku, Innovative Research Division</named-content>
<institution>Mitsubishi Tanabe Pharma Corporation</institution>
<city>Yokohama</city>
<named-content content-type="country-part">Kanagawa</named-content>
<country country="JP">Japan</country>
</aff><aff id="psp413023-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Systems Pharmacology, Non&#8208;Clinical Biomedical Science, Applied Research and Operations</named-content>
<institution>Astellas Pharma Inc.</institution>
<city>Ibaraki</city>
<country country="JP">Japan</country>
</aff><aff id="psp413023-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Sugiyama Laboratory, RIKEN Cluster for Science</named-content>
<institution>RIKEN</institution>
<city>Yokohama</city>
<named-content content-type="country-part">Kanagawa</named-content>
<country country="JP">Japan</country>
</aff><aff id="psp413023-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Drug Metabolism and Pharmacokinetics</named-content>
<institution>Janssen Research and Development, LLC</institution>
<city>San Diego</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="psp413023-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Drug Metabolism and Pharmacokinetics</named-content>
<institution>Janssen Research and Development</institution>
<city>Beerse</city>
<country country="BE">Belgium</country>
</aff><aff id="psp413023-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Quantitative System Pharmacokinetics/Pharmacodynamics</named-content>
<institution>Josai International University (JIU)</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Yuichi Sugiyama, Laboratory of Quantitative System Pharmacokinetics/Pharmacodynamics, School of Pharmacy, Josai International University, 2&#8208;3&#8208;11 Hirakawa&#8208;cho, Chiyoda&#8208;ku, Tokyo 102&#8208;0093, Japan.<break/>
Email: <email>y-sugiyama@jiu.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2023</year></pub-date><volume>12</volume><issue seq="90">10</issue><issue-id pub-id-type="pmc-issue-id">447523</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v12.10</issue-id><fpage>1461</fpage><lpage>1472</lpage><history><date date-type="rev-recd"><day>11</day><month>7</month><year>2023</year></date><date date-type="received"><day>27</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>19</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-26 01:25:13.463"><day>26</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 The Authors. <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-12-1461.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-12-1461.pdf"/><abstract><title>Abstract</title><p>The orally available anti&#8208;hepatitis C virus (HCV) drug simeprevir exhibits nonlinear pharmacokinetics at the clinical doses due to saturation of cytochrome P450 (CYP) 3A4 metabolism and organic anion transporting peptide (OATP) 1B mediated hepatic uptake. Additionally, simeprevir increases exposures of concomitant drugs by CYP3A4 and OATP1B inhibition. The objective of this study was to develop physiologically&#8208;based pharmacokinetic (PBPK) models that could describe drug&#8211;drug interactions (DDIs) of simeprevir with concomitant drugs via CYP3A4 and OATP1B inhibition, and also to capture the effects on coproporphyrin&#8208;I (CP&#8208;I), an endogenous biomarker of OATP1B. PBPK modeling estimated unbound simeprevir inhibitory constant (<italic toggle="no">K</italic>
<sub>i</sub>) of 2.89&#8201;&#956;M against CYP3A4 in the DDI results between simeprevir and midazolam in healthy volunteers. Then, we analyzed the DDIs between simeprevir and atorvastatin, a dual substrate of CYP3A4 and OATP1B, in healthy volunteers, and unbound <italic toggle="no">K</italic>
<sub>i</sub> against OATP1B was estimated to be 0.00347&#8201;&#956;M. Finally, we analyzed the increase in the blood level of CP&#8208;I by simeprevir to verify the <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub>. Because CP&#8208;I was measured in subjects with HCV with various hepatic fibrosis state, Monte Carlo simulation was performed to involve the decreases in expression levels of hepatic CYP3A4 and OATP1B and their interindividual variabilities. The PBPK modeling coupled with Monte Carlo simulation using the <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> value obtained from atorvastatin study reasonably recovered the observed relationship between CP&#8208;I and simeprevir blood levels. In conclusion, the simeprevir PBPK model developed in this study can quantitatively describe the increase in exposures of concomitant drugs and an endogenous biomarker via inhibition of CYP3A4 and OATP1B.</p></abstract><counts><fig-count count="5"/><table-count count="2"/><page-count count="12"/><word-count count="6703"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.4 mode:remove_FC converted:18.10.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PSP413023-cit-2001"><string-name name-style="western"><surname>Nakayama</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Physiologically&#8208;based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2023</year>;<volume>12</volume>:<fpage>1461</fpage>&#8208;<lpage>1472</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.13023</pub-id><pub-id pub-id-type="pmcid">PMC10583237</pub-id><pub-id pub-id-type="pmid">37667529</pub-id></mixed-citation>
</p></notes></front><body id="psp413023-body-0001"><p>
<boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="psp413023-list-0001"><list-item id="psp413023-li-0001"><p>
<bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>Simeprevir, an inhibitor of CYP3A4 and OATP1B, increases the exposures of concomitant drugs (midazolam and atorvastatin) in healthy subjects and an endogenous biomarker of OATP1B, CP&#8208;I, in patients with HCV.
<list list-type="simple" id="psp413023-list-0002"><list-item id="psp413023-li-0002"><p>
<bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>Can physiologically&#8208;based pharmacokinetic (PBPK) model analysis of simeprevir successfully capture the interactions with concomitant drugs and CP&#8208;I both in healthy subjects and patients with HCV?
<list list-type="simple" id="psp413023-list-0003"><list-item id="psp413023-li-0003"><p>
<bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>The simeprevir PBPK model coupled with Monte Carlo simulation can adequately recover the interactions with concomitant drugs and CP&#8208;I. Our analysis reveals that not only OATP1B increases inhibition by simeprevir but also decreases in expression levels of hepatic CYP3A4 and OATP1B due to progression of liver fibrosis can affect the relationship between simeprevir and CP&#8208;I blood levels in patients with HCV.
<list list-type="simple" id="psp413023-list-0004"><list-item id="psp413023-li-0004"><p>
<bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
</p></list-item></list>
</p><p>PBPK models taking interindividual difference and diseased conditions into account can reasonably describe the drug&#8211;drug and &#8208;endogenous biomarker interactions and will help the drug development and/or therapeutics.</p></boxed-text>
</p><sec id="psp413023-sec-0003"><title>INTRODUCTION</title><p>Simeprevir is an orally available drug for the treatment of hepatitis C virus (HCV) by inhibiting NS3/4A protease. Plasma exposures after single oral dose of simeprevir at the dose range from 50&#8201;mg to 600&#8201;mg have been evaluated in a phase I clinical trial in healthy volunteers (HVs). Plasma exposures increased dose&#8208;proportionally at the doses of 50&#8211;100&#8201;mg and greater than dose&#8208;proportionally at the doses of 150&#8211;600&#8201;mg.<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Simeprevir is a substrate of cytochrome P450 (CYP) 3A4, organic anion transporting peptide (OATP) 1B, and p&#8208;glycoprotein (P&#8208;gp).<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="psp413023-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> An analysis of simeprevir pharmacokinetics was performed using a physiologically&#8208;based pharmacokinetic (PBPK) model, and the results suggested that the saturation of CYP3A4 metabolism and the OATP1B mediated hepatic uptake were major factors for the nonlinear pharmacokinetics.<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> On the other hand, because a mass balance study demonstrated that the fraction absorbed of simeprevir at the dose of 50&#8201;mg was high (0.75),<xref rid="psp413023-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> it was considered that the impact of saturation of the P&#8208;gp mediated efflux at the intestinal tract on the nonlinear pharmacokinetics was limited.</p><p>It has been reported that co&#8208;administration of itraconazole, a potent CYP3A4 inhibitor, and rifampicin, an OATP1B inhibitor, increased the plasma exposure of simeprevir at the dose of 0.016&#8201;mg/kg.<xref rid="psp413023-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> In addition, it has been also reported that co&#8208;administration of ritonavir, erythromycin, and cyclosporine increased the plasma exposure of simeprevir at the dose of 150&#8201;mg, and their mechanisms were considered to be inhibition of CYP3A4, OATP1B, and P&#8208;gp.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Simeprevir is not only a substrate but also an inhibitor of CYP3A4 and OATP1B. In a clinical drug&#8211;drug interaction (DDI) study in HVs, simeprevir at the therapeutic dose of 150&#8201;mg q.d. increased the plasma area under the plasma concentration&#8208;time curve (AUC) of oral midazolam, a CYP3A4 probe substrate, by 1.45&#8208;fold. On the other hand, there was no impact of concomitant dosing of simeprevir on the intravenous midazolam AUC. This was likely due to simeprevir mainly inhibiting CYP3A4 in the intestinal tract, instead of liver. The 2.12&#8208;fold increase in the AUC of atorvastatin, a dual substrate of CYP3A4 and OATP1B, has been reported with co&#8208;administration of simeprevir at the dose of 150&#8201;mg q.d.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> In addition, plasma coproporphyrin&#8208;I (CP&#8208;I), an endogenous substrate of OATP1B, was measured in a clinical phase III study in subjects with HCV,<xref rid="psp413023-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> and it was confirmed that plasma CP&#8208;I concentrations increased where plasma simeprevir concentrations exceeded 3&#8201;&#956;M, suggesting that OATP1B inhibition by simeprevir was involved in the increase in plasma CP&#8208;I concentrations.<xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> It has also been reported that hepatic OATP1B expression level decreased with the progression of hepatic fibrosis in patients with HCV.<xref rid="psp413023-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Therefore, it is considered that decreases in OATP1B expression levels due to progression of hepatic fibrosis as well as OATP1B inhibition by simeprevir can be involved in the increase in plasma CP&#8208;I concentration observed in the clinical study.</p><p>Modeling approach is a powerful tool to predict and understand complex DDI quantitatively.<xref rid="psp413023-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp413023-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="psp413023-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="psp413023-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="psp413023-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp413023-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> PBPK model analysis with Monte Carlo sampling can describe not only average but also individual DDI. Whereas the PBPK model analysis for DDI of simeprevir as a victim drug has already been performed,<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> the quantitative model analysis investigating a series of DDIs of simeprevir as a perpetrator has not yet been done yet. In this study, the PBPK model analysis was performed on a series of DDIs in which simeprevir is a perpetrator drug. For highly lipophilic drugs, such as simeprevir,<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> it has been reported that inhibitory concentration of drug metabolizing enzymes and transporters determined by in vitro experiments may underpredict the magnitude of DDI in vivo due to high adsorption to experimental materials and protein components.<xref rid="psp413023-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Therefore, top&#8208;down estimation using PBPK modeling was performed to obtain in vivo inhibitory constant (<italic toggle="yes">K</italic>
<sub>i</sub>) of simeprevir against CYP3A4 and OATP1B by analyzing DDIs with midazolam and atorvastatin. Then, the effect of simeprevir on plasma CP&#8208;I level was simulated to verify <italic toggle="yes">K</italic>
<sub>i</sub> against OATP1B (<italic toggle="yes">K</italic>
<sub>i,OATP1B</sub>) using constructed PBPK model coupled with Monte Carlo sampling.</p></sec><sec sec-type="methods" id="psp413023-sec-0004"><title>METHODS</title><sec id="psp413023-sec-0005"><title>Development of simeprevir <styled-content style="fixed-case" toggle="no">PBPK</styled-content> model</title><p>The PBPK model structure and parameters of simeprevir are shown in Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1a</xref> and Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref>. The physiological parameters are shown in Table&#160;<xref rid="psp413023-supitem-0006" ref-type="supplementary-material">S1</xref>. The model code is available in the previous report.<xref rid="psp413023-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> The liver in this model consisted of extracellular and intracellular compartments, which were further divided into five parts to give a structure similar to the dispersion model.<xref rid="psp413023-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The reported overall intrinsic clearance (CL<sub>int,all</sub>), R<sub>dif</sub> (PS<sub>dif,inf</sub>/PS<sub>act,inf</sub>), &#947; (PS<sub>dif,inf</sub>/PS<sub>dif,eff</sub>), and &#946; ((CL<sub>int,met</sub>&#8201;+&#8201;CL<sub>int,bile</sub>)/(PS<sub>dif,eff</sub>&#8201;+&#8201;CL<sub>int,met</sub>&#8201;+&#8201;CL<sub>int,bile</sub>)) were used.<xref rid="psp413023-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The reported kinetic metabolite (<italic toggle="yes">K</italic>
<sub>m</sub>) for CYP3A4 metabolism and OATP1B mediated hepatic uptake were also used to capture the nonlinear pharmacokinetics.<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Enterohepatic circulation was described by connecting the hepatocytes and intestinal lumen compartments with three tandem transit compartments. The intestinal tract was divided into luminal and cellular compartments,<xref rid="psp413023-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and intestinal CYP3A4 metabolism of simeprevir was considered. Muscle, adipose, and skin were selected as the distribution organs, and the blood to tissue concentration ratio (<italic toggle="yes">K</italic>
<sub>p</sub>) in each organ was predicted based on logP, pK<sub>a</sub>, and plasma unbound fraction.<xref rid="psp413023-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="psp413023-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The measured plasma concentrations were converted to blood concentrations by correcting the blood to plasma concentration ratio. The effective permeability (<italic toggle="yes">P</italic>
<sub>eff</sub>) in the intestinal tract and the passive diffusion ratio between from enterocyte to intestinal lumen and from enterocyte to mucosal blood (AR) were optimized simultaneously to recover the blood concentration&#8208;time profiles of simeprevir at the six dose levels from 50&#8201;mg to 600&#8201;mg. All DDI studies were conducted at a dose level of 150&#8201;mg q.d. simeprevir.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Nonetheless, plasma simeprevir concentrations after once daily dosing at a dose of 150&#8201;mg in subjects with HCV were distributed in a wide range (~20&#8211;40,000&#8201;ng/mL) in the clinical trial investigating the effect on CP&#8208;I. Interindividual variability in drug clearance and nonlinear pharmacokinetics may result in this study outcome. Therefore, it was required to describe nonlinear pharmacokinetics and interindividual variability of simeprevir in the present study.</p><fig position="float" fig-type="FIGURE" id="psp413023-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Structures of PBPK model of simeprevir (a), midazolam (b),<xref rid="psp413023-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> atorvastatin (c),<xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> and coproporphyrin&#8208;I (d).<xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="psp413023-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The liver compartment was further divided into five subcompartments to construct a model similar to the dispersion model.<xref rid="psp413023-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> PBPK models for simeprevir, atorvastatin, and coproporphyrin&#8208;I were developed assuming a perfusion rate&#8208;limited distribution, whereas a rapid equilibrium for midazolam. Enterohepatic circulation was incorporated for simeprevir, atorvastatin and coproporphyrin&#8208;I. Portal vein blood flow was divided into mucosal and serosal blood flow for simeprevir.<xref rid="psp413023-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> CL<sub>bile</sub>, intrinsic clearance of biliary excretion; CL<sub>int,met</sub>, intrinsic clearance of hepatic metabolism; CL<sub>R</sub>, renal clearance; CL<sub>met,ent</sub>, intrinsic clearance of intestinal metabolism; <italic toggle="yes">F</italic>
<sub>a</sub>, fraction absorbed; <italic toggle="yes">F</italic>
<sub>g</sub>, intestinal metabolic availability; <italic toggle="yes">f</italic>
<sub>b</sub>, protein unbound fraction in blood; <italic toggle="yes">f</italic>
<sub>h</sub>, hepatic protein unbound fraction; <italic toggle="yes">f</italic>
<sub>u,gut</sub>, unbound fraction in enterocyte; <italic toggle="yes">f</italic>
<sub>syn</sub>, fraction of CP&#8208;I biosynthesis in the liver; <italic toggle="yes">k</italic>
<sub>a</sub>, absorption rate constant; <italic toggle="yes">K</italic>
<sub>p</sub>, tissue/blood concentration ratio; <italic toggle="yes">k</italic>
<sub>bile</sub>, transit rate constant for enterohepatic circulation; PBPK, physiologically&#8208;based pharmacokinetic; PS<sub>actinf,h</sub>, active uptake intrinsic clearance on sinusoidal membrane; PS<sub>difinf,ent</sub>, influx clearance by passive diffusion through basolateral membranes from the mucosal blood to the enterocyte; PS<sub>difinf,h</sub>, influx intrinsic clearance by passive diffusion through sinusoidal membrane; PS<sub>difeff,ent</sub>, efflux clearance by passive diffusion through a basolateral membrane from the enterocyte to the mucosal blood; PS<sub>difeff,h</sub>, efflux intrinsic clearance by passive diffusion through sinusoidal membrane; <italic toggle="yes">Q</italic>
<sub>tissue</sub>, blood flow rate in tissue; <italic toggle="yes">V</italic>
<sub>syn</sub>, rate of CP&#8208;I biosynthesis in the whole body; <italic toggle="yes">V</italic>
<sub>tissue</sub>, tissue volume.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-12-1461-g002.jpg"/></fig><table-wrap position="float" id="psp413023-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Fixed and optimized PBPK model parameters of simeprevir.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="left" valign="bottom" rowspan="1" colspan="1">Fixed</th><th align="left" valign="bottom" rowspan="1" colspan="1">Optimized, CV% (Initial)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unit</th><th align="left" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
<sub>eff</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">0.189, 7.04% (0.504)</td><td align="left" valign="top" rowspan="1" colspan="1">10<sup>&#8722;4</sup>&#8201;cm/s</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AR</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4.79, 2.79% (1.00)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>b</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.00139</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sub>B</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>h</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.0147</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>u,gut</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.095</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">19,20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>p,skin</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.389</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>p,muscle</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>p,adipose</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.0743</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>p,gut</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.222</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">19,20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>m,u,CYP3A4</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">7.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#956;g/L</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>max,CYP3A4</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">1740</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#956;g/h</td><td align="left" valign="top" rowspan="1" colspan="1">Calculated from 1 and 4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>m,CYP3A4</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.81</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>m,u,OATPIB</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.25</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#956;g/L</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>max,OATP1B</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">70,500</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#956;g/h</td><td align="left" valign="top" rowspan="1" colspan="1">Calculated from 1 and 4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL<sub>R</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">L/h</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL<sub>int,all</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">6970</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">L/h</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sub>dif</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.0113</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>bile</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#947;</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#946;</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.22</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>i,u,CYP3A4</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">2170, 23.9% (89100)</td><td align="left" valign="top" rowspan="1" colspan="1">&#956;g/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>i,u,OATP1B</sub>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">2.60, 6.73% (525)</td><td align="left" valign="top" rowspan="1" colspan="1">&#956;g/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot id="psp413023-ntgp-0001"><fn id="psp413023-note-0001"><p>
<italic toggle="yes">Note</italic>: <italic toggle="yes">R</italic>
<sub>dif</sub>&#8201;=&#8201;PS<sub>dif,inf</sub>/PS<sub>act,inf</sub>, <italic toggle="yes">f</italic>
<sub>bile</sub>&#8201;=&#8201;CL<sub>int,bile</sub>/(CL<sub>int,met</sub>&#8201;+&#8201;CL<sub>int,bile</sub>), <italic toggle="yes">&#947;</italic>&#8201;=&#8201;PS<sub>dif,inf</sub>/PS<sub>dif,eff</sub>, <italic toggle="yes">&#946;</italic>&#8201;=&#8201;(CL<sub>int,met</sub>&#8201;+&#8201;CL<sub>int,bile</sub>)/(PS<sub>dif,eff</sub>&#8201;+&#8201;CL<sub>int,met</sub>&#8201;+&#8201;CL<sub>int,bile</sub>).</p><p>Comparable CL<sub>int,all</sub> (10,800&#8201;L/h) was reported by Snoeys et al. assuming following scaling parameters (111&#8201;pmol CYP3A4/mg microsomal protein, 99 million cells/g liver, 32&#8201;mg microsomal protein/g liver and 1799&#8201;g liver/body).<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="psp413023-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="psp413023-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p><p>
<italic toggle="yes">V</italic>
<sub>max,CYP3A4</sub> was calculated by (1 &#8722; <italic toggle="yes">f</italic>
<sub>bile</sub>)&#65381;<italic toggle="yes">&#946;</italic>&#65381;CL<sub>int,all</sub>&#65381;<italic toggle="yes">R</italic>
<sub>dif</sub>&#65381;<italic toggle="yes">f</italic>
<sub>m,CYP3A4</sub>&#65381;K<sub>m,u,CYP3A4</sub>/((1 &#8722; <italic toggle="yes">&#946;</italic>)&#65381;<italic toggle="yes">&#947;</italic>&#65381;<italic toggle="yes">&#946;</italic>&#65381;(1&#8201;+&#8201;<italic toggle="yes">R</italic>
<sub>dif</sub>)).</p><p>
<italic toggle="yes">V</italic>
<sub>max,OATP1B</sub> was calculated by CL<sub>int,all</sub>&#65381;K<sub>m,u,OATPIB</sub>/(<italic toggle="yes">&#946;</italic>&#65381;(1&#8201;+&#8201;<italic toggle="yes">R</italic>
<sub>dif</sub>)).</p><p>
<italic toggle="yes">K</italic>
<sub>p,tissue</sub> and <italic toggle="yes">f</italic>
<sub>u,gut</sub> were calculated as previously reported by Rodgers and Rowland.<xref rid="psp413023-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="psp413023-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>
<italic toggle="yes">K</italic>
<sub>i,u,CYP3A4</sub> of 2170&#8201;&#956;g/L corresponds to 2.89&#8201;&#956;M, <italic toggle="yes">K</italic>
<sub>i,u,OATP1B</sub> of 2.60&#8201;&#956;g/L corresponds to 0.00347&#8201;&#956;M.</p></fn><fn id="psp413023-note-0002"><p>Abbreviations: AR, apical to basolateral intestinal membrane surface area ratio; CL<sub>int,all</sub>, overall intrinsic hepatic clearance; CL<sub>int,bile</sub>, intrinsic biliary excretion clearance; CL<sub>int,met</sub>, intrinsic metabolic clearance; CL<sub>R</sub>, renal clearance; CV%, coefficient of variation percentage; <italic toggle="yes">f</italic>
<sub>b</sub>, blood unbound fraction; EHC, entero&#8208;hepatic circulation; <italic toggle="yes">f</italic>
<sub>u,gut</sub>, unbound fraction in enterocytes; <italic toggle="yes">f</italic>
<sub>h</sub>, unbound fraction in hepatocytes; <italic toggle="yes">f</italic>
<sub>m,CYP3A4</sub>, fraction metabolized for CYP3A4; <italic toggle="yes">K</italic>
<sub>i,u,CYP3A4</sub>, unbound inhibition constant against CYP3A4; <italic toggle="yes">K</italic>
<sub>i,u,OATP1B</sub>, unbound inhibition constant against OATP1B; <italic toggle="yes">K</italic>
<sub>m,u,CYP3A4</sub>, unbound Michaelis&#8211;Menten constant for CYP3A4; <italic toggle="yes">K</italic>
<sub>m,u,OATP1B</sub>, unbound Michaelis&#8211;Menten constant for OATP1B; <italic toggle="yes">K</italic>
<sub>p</sub>, tissue, tissue to blood tissue partition coefficients; PBPK, physiologically&#8208;based pharmacokinetic; <italic toggle="yes">P</italic>
<sub>eff</sub>, effective permeability; PS<sub>act,inf</sub>, active uptake intrinsic clearance on sinusoidal membrane; PS<sub>dif,eff</sub>, efflux intrinsic clearance by passive diffusion through sinusoidal membrane; PS<sub>dif,inf</sub>, influx intrinsic clearance by passive diffusion through sinusoidal membrane; <italic toggle="yes">R</italic>
<sub>B</sub>, blood to plasma concentration ratio; <italic toggle="yes">V</italic>
<sub>max,CYP3A4</sub>, maximum velocity for CYP3A4; <italic toggle="yes">V</italic>
<sub>max,OATP1B</sub>, maximum velocity for OATP1B.</p></fn></table-wrap-foot></table-wrap></sec><sec id="psp413023-sec-0006"><title>DDI analysis of simeprevir and midazolam</title><p>The effect of simeprevir multiple dose (150&#8201;mg q.d.) on the blood concentration&#8208;time profiles of midazolam after oral and intravenous administrations were evaluated in healthy subjects.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> The PBPK model structure and parameters of midazolam are shown in Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1b</xref> and Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>. The published PBPK model structure was used.<xref rid="psp413023-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> A rapid equilibrium distribution to the liver was assumed. Intestinal absorption was described by <italic toggle="yes">Q</italic>
<sub>gut</sub> model to take its intestinal metabolism into consideration. The absorption rate constant (<italic toggle="yes">k</italic>
<sub>a</sub>), CL<sub>int,all</sub>, and scaling factor of <italic toggle="yes">K</italic>
<sub>p</sub> (<italic toggle="yes">Y</italic>
<sub>Kp</sub>) were optimized simultaneously to reproduce the time course of midazolam blood concentration after intravenous and oral administration in the absence of simeprevir. Then, we estimated the <italic toggle="yes">K</italic>
<sub>i</sub> of simeprevir against CYP3A4 (<italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub>) to reproduce the changes in blood concentrations of midazolam after intravenous and oral administration with co&#8208;administration of simeprevir at the dose of 150&#8201;mg. The reported nominal half&#8208;maximal inhibitory concentration (IC<sub>50</sub>) of simeprevir against CYP3A4 determined by in vitro experiments using human liver microsomes was used as an initial value.<xref rid="psp413023-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p></sec><sec id="psp413023-sec-0007"><title>DDI analysis of simeprevir and atorvastatin</title><p>The changes in blood concentration&#8208;time profiles of atorvastatin, a dual substrate of CYP3A4 and OATP1B, after co&#8208;administration of simeprevir at the dose of 150&#8201;mg q.d. were also evaluated in healthy subjects.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> The PBPK model structure and parameters of atorvastatin are shown in Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1c</xref> and Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>. The model structure of the intestinal tract was changed from the first&#8208;order absorption model used in the previous study to the <italic toggle="yes">Q</italic>
<sub>gut</sub> model to consider the inhibitory effect of simeprevir on intestinal CYP3A4.<xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Each liver compartment was divided into extrahepatic and hepatocellular compartments to incorporate the hepatic uptake process mediated by OATP1B. The model also accounted for enterohepatic recirculation because atorvastatin was excreted into bile as the unchanged drug.<xref rid="psp413023-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The <italic toggle="yes">k</italic>
<sub>a</sub>, CL<sub>int,all</sub>, and <italic toggle="yes">Y</italic>
<sub>Kp</sub> were optimized simultaneously to reproduce the time course of atorvastatin blood concentration in the absence of simeprevir. Then, <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> was set at the value estimated in the analysis of DDI with midazolam, and the <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> was estimated to reproduce the increase of atorvastatin blood concentration with co&#8208;administration of simeprevir at the dose of 150&#8201;mg. The experimentally determined IC<sub>50</sub> value of simeprevir against OATP1B using expression cell system was used as an initial value.<xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p></sec><sec id="psp413023-sec-0008"><title>Analysis of interactions between simeprevir and CP&#8208;I</title><p>The effect of simeprevir multiple dose (150&#8201;mg q.d.) on CP&#8208;I plasma levels was assessed in a phase III clinical trial for the evaluation of long&#8208;term efficacy and safety in subjects with HCV.<xref rid="psp413023-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> The PBPK model structure and parameters of CP&#8208;I are shown in Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1d</xref> and Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>. The membrane limited hepatic uptake by OATP1B and enterohepatic circulation were considered as well as simeprevir and atorvastatin.<xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="psp413023-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The study outline of an actual clinical trial and virtual clinical trials evaluating the increase in plasma CP&#8208;I concentration by simeprevir are summarized in Table&#160;<xref rid="psp413023-supitem-0008" ref-type="supplementary-material">S3</xref>. The dosing amount of simeprevir, dosing duration, the total number of subjects, and the proportion of subjects with each METAVIR fibrosis score among all subjects were set at the same condition in actual and virtual clinical trials. Approximately one&#8208;third of subjects had METAVIR fibrosis score of F1 (mild fibrosis). Another one&#8208;third had fibrosis score of F2 (significant fibrosis), and the rest had fibrosis score of F3 (severe fibrosis) or F4 (cirrhosis).<xref rid="psp413023-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> It has been reported that the progression of liver fibrosis resulted in altering the expression levels of CYP3A4 and OATP1B,<xref rid="psp413023-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> which may affect the exposures of simeprevir and CP&#8208;I. Therefore, the decrease in the expression level of CYP3A4 and OATP1B in subjects with HCV with each METAVIR fibrosis score and its interindividual variations were incorporated to conduct the Monte Carlo simulation. <italic toggle="yes">V</italic>
<sub>max,CYP3A4</sub> and <italic toggle="yes">V</italic>
<sub>max,OATP1B</sub> for simeprevir in subjects with HCV were calculated by multiplying those in HVs and ratio of expression level in subjects with HCV to HVs. Similar to that, an active uptake intrinsic clearance on sinusoidal membrane mediated by OATP1B for CP&#8208;I in subjects with HCV was obtained by multiplying that in HVs and ratio of expression level in subjects with HCV to HVs. The interindividual variability in the renal clearance of CP&#8208;I was also considered and assumed to be comparable between healthy and HCV subjects (Table&#160;<xref rid="psp413023-supitem-0009" ref-type="supplementary-material">S4</xref>).<xref rid="psp413023-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The interindividual variabilities of other parameters were not considered in the present study. The synthesis of CP&#8208;I was assumed to be constant between HVs and subjects with HCV. Because both simeprevir and CP&#8208;I were low systemic clearance substances,<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> the change in hepatic blood flow and its variability might have limited impact on study outcomes. Plasma samples were collected immediately before (<italic toggle="yes">C</italic>
<sub>trough</sub>) and 1&#8211;7&#8201;hours after dose at 2, 4, 8, and 12&#8201;weeks after the initial dose in the actual clinical study, whereas plasma samples were collected immediately before and 2&#8201;hours after dose at 2 and 12&#8201;weeks after the initial dose in the virtual clinical study (Table&#160;<xref rid="psp413023-supitem-0008" ref-type="supplementary-material">S3</xref>). The reasons for adopting the simplified blood sampling in virtual clinical trials are described in the Results section. Six virtual clinical trials were performed with the fixed <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> that was estimated from drug interaction with atorvastatin, and compared to an actual clinical trial.</p></sec><sec id="psp413023-sec-0009"><title>Software</title><p>The parameter estimation and simulation were conducted by Phoenix WinNonLin version 8.1 (Certara USA). The weight for the nonlinear least&#8208;squares calculation was set as the square root of the observed value. The <italic toggle="yes">P</italic>
<sub>eff</sub> was predicted by ADMET predictor version 9.5 (Simulation Plus) for simeprevir and atorvastatin. The generation of virtual patient populations was performed with R version 4.2.0, as described previously.<xref rid="psp413023-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec></sec><sec sec-type="results" id="psp413023-sec-0010"><title>RESULTS</title><sec id="psp413023-sec-0011"><title>PBPK model development to describe nonlinear pharmacokinetics of simeprevir</title><p>The observed blood concentration&#8208;time profiles between 50&#8201;mg and 600&#8201;mg simeprevir doses in healthy subjects was captured well by optimizing <italic toggle="yes">P</italic>
<sub>eff</sub> and AR (Figure&#160;<xref rid="psp413023-fig-0002" ref-type="fig">2</xref>). These parameters were converged with small coefficient of variation (CV) values of 7.04 and 2.79%, respectively. The fixed and optimized PBPK model parameters of simeprevir are shown in Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref> and the physiological parameters in Table&#160;<xref rid="psp413023-supitem-0006" ref-type="supplementary-material">S1</xref>. The observed and optimized blood AUC and maximum plasma concentration (<italic toggle="yes">C</italic>
<sub>max</sub>) of simeprevir were summarized in Figure&#160;<xref rid="psp413023-supitem-0002" ref-type="supplementary-material">S1</xref>.</p><fig position="float" fig-type="FIGURE" id="psp413023-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Optimized and observed simeprevir blood concentration&#8208;time profiles after single oral administration at the doses of 50&#8201;mg (a), 100&#8201;mg (b), 200&#8201;mg (c), 300&#8201;mg (d), 450&#8201;mg (e), and 600&#8201;mg (f) in healthy volunteers. The open circles represent observed concentration&#8208;time profiles.<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Each solid line represents an optimized concentration&#8208;time profile using PBPK model and parameters shown in Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1a</xref> and Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref>. PBPK, physiologically&#8208;based pharmacokinetic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-12-1461-g005.jpg"/></fig></sec><sec id="psp413023-sec-0012"><title>Increase in midazolam exposure via CYP3A4 inhibition by simeprevir in healthy subjects</title><p>Midazolam blood concentrations after intravenous and oral administration alone can be reproduced by optimizing <italic toggle="yes">k</italic>
<sub>a</sub>, CL<sub>int,all</sub>, and <italic toggle="yes">Y</italic>
<sub>Kp</sub> (Figure&#160;<xref rid="psp413023-fig-0003" ref-type="fig">3</xref>). The fixed and optimized PBPK model parameters for midazolam are shown in Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>. The <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> of simeprevir was estimated to be 2.89&#8201;&#956;M (CV, 23.9%) to recover the increase in oral midazolam exposure in the presence of simeprevir (Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref>). Simulated <italic toggle="yes">C</italic>
<sub>max</sub> and AUC fold&#8208;increase in oral midazolam exposure by simeprevir dosing were 1.46 and 1.49&#8208;fold, whereas those observed in the clinical study were 1.31 and 1.45&#8208;fold, respectively.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> On the other hand, co&#8208;administration of simeprevir showed no apparent change in intravenous midazolam exposure. These results were in line with observed data (Table&#160;<xref rid="psp413023-tbl-0002" ref-type="table">2</xref> and Figure&#160;<xref rid="psp413023-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413023-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Optimized and observed blood concentration&#8208;time profiles of oral (a) and intravenous (b) midazolam before and after simeprevir once daily oral administrations at the dose of 150&#8201;mg for 10&#8201;days (oral midazolam) and 11&#8201;days (intravenous midazolam) in healthy volunteers. Oral and intravenous midazolam were administered at the doses of 0.075&#8201;mg/kg and 0.025&#8201;mg/kg, respectively.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> The black and red circles represent observed blood midazolam concentrations in the absence and presence of simeprevir, respectively. The circles and bars represent measured concentrations and their SD values, respectively. The black and red lines represent optimized blood midazolam concentration&#8208;time profiles in the absence and presence of simeprevir, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-12-1461-g001.jpg"/></fig><table-wrap position="float" id="psp413023-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Observed and optimized fold increase in AUC and <italic toggle="no">C</italic>
<sub>max</sub> of midazolam and atorvastatin following once daily multiple oral simeprevir dosing in healthy volunteers.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Victim drug</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Mean ratio (90% CI) with/without simeprevir</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>
</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">AUC</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Observed</th><th align="left" valign="bottom" rowspan="1" colspan="1">Simulated</th><th align="left" valign="bottom" rowspan="1" colspan="1">Observed</th><th align="left" valign="bottom" rowspan="1" colspan="1">Simulated</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Midazolam (i.v.)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.78 (0.52&#8211;1.17)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.00</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.10 (0.95&#8211;1.26)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Midazolam (p.o.)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.31 (1.19&#8211;1.45)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.46</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.45 (1.35&#8211;1.57)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.49</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Atorvastatin (p.o.)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.70 (1.42&#8211;2.04)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.69</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.12 (1.72&#8211;2.62)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.38</td></tr></tbody></table><table-wrap-foot id="psp413023-ntgp-0002"><fn id="psp413023-note-0003"><p>
<italic toggle="yes">Note</italic>: Midazolam was administered at the doses of 0.075&#8201;mg/kg orally and 0.025&#8201;mg/kg intravenously. Atorvastatin was administered orally at the dose of 40&#8201;mg. Simeprevir was administered at the dose of 150&#8201;mg for 11&#8201;days for intravenous midazolam and 10&#8201;days for oral midazolam and atorvastatin.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p></fn><fn id="psp413023-note-0004"><p>Abbreviations: AUC, area under the concentration&#8208;time curve; CI, confidence interval; <italic toggle="yes">C</italic>
<sub>max</sub>, maximum plasma concentration.</p></fn></table-wrap-foot></table-wrap></sec><sec id="psp413023-sec-0013"><title>Increase in atorvastatin exposure via CYP3A4 and OATP1B inhibition of simeprevir in healthy subjects</title><p>A blood concentration&#8211;time profile of atorvastatin in the absence of concomitant drugs was reproduced by optimizing <italic toggle="yes">k</italic>
<sub>a</sub>, CL<sub>int,all</sub>, and <italic toggle="yes">Y</italic>
<sub>Kp</sub> (Figure&#160;<xref rid="psp413023-fig-0004" ref-type="fig">4</xref>). The fixed and optimized PBPK model parameters of atorvastatin are shown in Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>. When <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> was set at the value obtained by the analysis of DDI with midazolam (2.89&#8201;&#956;M), <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> was estimated to be 0.00347&#8201;&#956;M (CV, 6.73%) to recover the increase in atorvastatin exposure by coadministration of simeprevir (Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref>). The simulated increase in atorvastatin <italic toggle="yes">C</italic>
<sub>max</sub> and AUC were 2.69 and 2.38&#8208;fold, whereas those observed in the clinical study were 1.70 and 2.12&#8208;fold, respectively (Table&#160;<xref rid="psp413023-tbl-0002" ref-type="table">2</xref> and Figure&#160;<xref rid="psp413023-fig-0004" ref-type="fig">4</xref>).<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="psp413023-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Optimized and observed blood concentration&#8208;time profiles of atorvastatin before and after simeprevir once daily oral administrations at the dose of 150&#8201;mg for 10&#8201;days in healthy volunteers. Atorvastatin was administered orally at the dose of 40&#8201;mg.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> The black and red circles represent observed blood atorvastatin concentration in the absence and presence of simeprevir, respectively. The circles and bars represent measured concentrations and their SD values. The black and red lines represent optimized blood atorvastatin concentration&#8208;time profiles in the absence and presence of simeprevir, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PSP4-12-1461-g004.jpg"/></fig></sec><sec id="psp413023-sec-0014"><title>Relationship between simeprevir and <styled-content style="fixed-case" toggle="no">CP&#8208;I</styled-content> blood concentrations in subjects with HCV</title><p>When <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> was set at the value estimated by the analysis of DDIs with atorvastatin (0.00347&#8201;&#956;M), a total of six virtual clinical trials of the same size as the clinical trial were conducted, and the results are shown in Figure&#160;<xref rid="psp413023-fig-0005" ref-type="fig">5</xref>. When conducting virtual clinical studies, decreases in expression levels of hepatic CYP3A4 and OATP1B in subjects with HCV with each METAVIR fibrosis score compared to healthy subjects were considered. In addition, interindividual variabilities for hepatic CYP3A4 expression level, OATP1B expression level,<xref rid="psp413023-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="psp413023-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and CP&#8208;I renal clearance were also incorporated (Table&#160;<xref rid="psp413023-supitem-0009" ref-type="supplementary-material">S4</xref>).<xref rid="psp413023-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The CP&#8208;I blood concentrations were in a similar range around 0.6&#8201;nM when the simeprevir blood concentration were below ~2000&#8201;ng/mL, and then increased up to 6&#8201;nM at the simeprevir blood concentration range from 2000 to 30,000&#8201;ng/mL in the actual clinical trial (Figure&#160;<xref rid="psp413023-fig-0005" ref-type="fig">5a</xref>).<xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> All virtual clinical trials adequately predicted this trend (Figure&#160;<xref rid="psp413023-fig-0005" ref-type="fig">5b&#8211;h</xref>). Simulation results indicated that some subjects with METAVIR fibrosis scores of F1 and F2 showed CP&#8208;I concentrations around the baseline, whereas many of F3 and F4 subjects showed high blood concentrations of both simeprevir and CP&#8208;I.</p><fig position="float" fig-type="FIGURE" id="psp413023-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Observed (a) and simulated (b&#8211;h) relationship between blood concentrations of CP&#8208;I and simeprevir in subjects with HCV. Gray circles represent observed data. Red, green, blue, and yellow circles represent and simulated data in subjects with HCV with METAVIR fibrosis score F1, F2, F3, and F4, respectively. Simeprevir was orally administered once daily at the dose of 150&#8201;mg.<xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Plasma samples were prepared from 2 to 12&#8201;weeks after first dose. Detailed study conditions were shown in Table&#160;<xref rid="psp413023-supitem-0008" ref-type="supplementary-material">S3</xref>. CP&#8208;I, coproporphyrin&#8208;I; HCV, hepatitis C virus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PSP4-12-1461-g003.jpg"/></fig><p>Besides the phase III clinical trial investigating the relationship between CP&#8208;I and simeprevir, the plasma concentration&#8208;time profile of simeprevir in representative subjects with HCV (METAVIR fibrosis score not assigned) was also reported.<xref rid="psp413023-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The observed and simulated blood concentration&#8208;time profiles after single oral administration of simeprevir at the doses of 75&#8201;mg, 150&#8201;mg, and 200&#8201;mg in representative patients with HCV are shown in Figure&#160;<xref rid="psp413023-supitem-0003" ref-type="supplementary-material">S2</xref>. The simulated blood concentration&#8208;time profiles in subjects with HCV with METAVIR fibrosis scores of F1 and F2, who accounted for 67% among all participants in the phase III clinical trial, seemed to capture the observed data in representative subjects with HCV. The simulated concentrations of unbound simeprevir in liver sinusoids, hepatocytes, and enterocytes at steady&#8208;state after once&#8208;daily oral administration of simeprevir at the dose of 150&#8201;mg for 12&#8201;weeks are shown in Figure&#160;<xref rid="psp413023-supitem-0004" ref-type="supplementary-material">S3</xref>. The optimized <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> and <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> are overlaid.</p></sec></sec><sec sec-type="discussion" id="psp413023-sec-0015"><title>DISCUSSION</title><p>In this study, a series of DDIs of simeprevir as a perpetrator were analyzed by PBPK modeling coupled with Monte Carlo simulation to estimate and verify the in vivo <italic toggle="yes">K</italic>
<sub>i</sub> of simeprevir against CYP3A4 and OATP1B.</p><p>Because it has been reported that the saturation of CYP3A4 metabolism and hepatic uptake mediated by OATP1B contributed the nonlinear pharmacokinetics of simeprevir, a PBPK model structure, including CYP3A4 metabolism in the small intestine and liver, hepatic uptake by OATP1B was adopted.<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="psp413023-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="psp413023-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> The model also accounted for enterohepatic recirculation because simeprevir was excreted into bile as the unchanged drug (Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1a</xref>).<xref rid="psp413023-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The values of parameters related to drug systemic clearance, such as CL<sub>int,all</sub>, <italic toggle="yes">V</italic>
<sub>max</sub>, and <italic toggle="yes">K</italic>
<sub>m</sub> were obtained from the previous reports.<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="psp413023-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The concentration&#8208;time profiles of simeprevir at the doses from 50 to 600&#8201;mg in healthy subjects were reproduced by optimizing two parameters related to intestinal absorption, <italic toggle="yes">P</italic>
<sub>eff</sub> and AR (Figure&#160;<xref rid="psp413023-fig-0002" ref-type="fig">2</xref> and Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref>). If AR was fixed to be unity and only <italic toggle="yes">P</italic>
<sub>eff</sub> was optimized, nonlinear pharmacokinetics of simeprevir was also adequately captured (data not shown). These results indicated that AR had limited impact on nonlinearity in this case, but <italic toggle="yes">K</italic>
<sub>m</sub> for OATP1B and CYP3A4 were key parameters to capture the nonlinearity.</p><p>The reported PBPK model structure of midazolam was used in this study.<xref rid="psp413023-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> By optimizing <italic toggle="yes">k</italic>
<sub>a</sub>, CL<sub>int,all</sub>, and <italic toggle="yes">Y</italic>
<sub>Kp</sub> of midazolam, the time course of blood midazolam concentration without concomitant use of simeprevir was reproduced. It has been reported that simeprevir shows the competitive inhibition against CYP3A4, but not time&#8208;dependent inhibition.<xref rid="psp413023-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The unbound <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> was estimated to be 2.89&#8201;&#956;M with the reasonable CV value of 23.9% using PBPK model analysis (Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref> and Figure&#160;<xref rid="psp413023-fig-0003" ref-type="fig">3</xref>). Simulated unbound simeprevir concentrations in enterocyte compartment exceeded the optimized unbound <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> up to 6&#8211;8&#8201;h postdose, indicating the inhibition of intestinal CYP3A4 activity by simeprevir. On the other hand, simeprevir was unlikely inhibit the hepatic CYP3A4 in hepatocytes because the simulated unbound simeprevir concentrations in hepatocytes were 100&#8208;fold lower than <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> over the entire dosing interval (Figure&#160;<xref rid="psp413023-supitem-0004" ref-type="supplementary-material">S3b,c</xref>). These were consistent with the observation that co&#8208;administration of simeprevir increased the exposure of orally administered midazolam but had little effect on the exposure of intravenously administered midazolam.<xref rid="psp413023-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> As a result of in vitro study using human liver microsomes, the nominal IC<sub>50</sub> values of simeprevir were determined to be 84.5 and 153&#8201;&#956;M for 4&#8208; and 1&#8242;&#8208;midazolam hydroxylase activities, respectively.<xref rid="psp413023-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> By considering the unbound fraction in incubation determined by in vitro binding experiments, unbound IC<sub>50</sub> was estimated to be 0.455&#8211;0.823&#8201;&#956;M. <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> obtained by the PBPK model analysis (2.89&#8201;&#956;M) was not significantly different from the range of inhibitory concentration determined in the in vitro studies.</p><p>The model structure of the intestinal absorption of atorvastatin was modified from the previously reported first&#8208;order absorption to the <italic toggle="yes">Q</italic>
<sub>gut</sub> model to incorporate CYP3A4 metabolism in the enterocytes, enabled us to consider the inhibition of intestinal CYP3A4 activity by simeprevir. The PBPK model structure and values of parameters related distribution, metabolism, and excretion of atorvastatin were obtained from the previous reports (Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1c</xref> and Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>).<xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> When unbound <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> was set at the value obtained by the PBPK analysis with midazolam (2.89&#8201;&#956;M), unbound <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> was estimated to be 0.00347&#8201;&#956;M with the small CV value of 6.73% (Table&#160;<xref rid="psp413023-tbl-0001" ref-type="table">1</xref> and Figure&#160;<xref rid="psp413023-fig-0004" ref-type="fig">4</xref>). The simulated unbound <italic toggle="yes">C</italic>
<sub>max</sub> of simeprevir in the liver sinusoid compartment exceeded <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> in healthy subjects (Figure&#160;<xref rid="psp413023-supitem-0004" ref-type="supplementary-material">S3a</xref>). The nominal IC<sub>50</sub> values of simeprevir against OATP1B1 and 1B3 determined by the expression cell system were reported to be 0.7 and 0.6&#8201;&#956;M, respectively.<xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> These values were ~200&#8208;fold higher than unbound <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> estimated by the PBPK model analysis (0.00347&#8201;&#956;M), possibly due to high nonspecific binding to cellular components and experimental materials. On the other hand, the <italic toggle="yes">K</italic>
<sub>m,OATP1B</sub> of simeprevir estimated by PBPK model analysis was reported to be 0.003&#8201;&#956;M,<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> which was close to <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> obtained in this study.</p><p>The reported PBPK model structure and parameters of CP&#8208;I constructed by authors (Sugiyama and his co&#8208;workers) were used in this study (Figure&#160;<xref rid="psp413023-fig-0001" ref-type="fig">1d</xref> and Table&#160;<xref rid="psp413023-supitem-0007" ref-type="supplementary-material">S2</xref>).<xref rid="psp413023-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="psp413023-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Blood samples were collected at multiple timepoints up to 7&#8201;h after dose at 2, 4, 8, and 12&#8201;weeks in the actual clinical trial. However, sampling points were set at 0 and 2&#8201;h after the dose, corresponding to trough and peak concentrations, at 2 and 12&#8201;weeks in the virtual clinical trials. The reasons for these differences are (1) blood sampling timepoints at 0 and 2&#8201;h postdose accounted for 70% of total samples, (2) ~40% of samples were collected at week 2, followed by 12&#8201;weeks (Table&#160;<xref rid="psp413023-supitem-0010" ref-type="supplementary-material">S5</xref>), (3) the blood concentrations of simeprevir and CP&#8208;I seemed to be a similar range across entire weeks, indicating that those of both substances reached steady&#8208;state at week 2 in the actual clinical study (Figure&#160;<xref rid="psp413023-supitem-0005" ref-type="supplementary-material">S4</xref>). The highest blood simeprevir concentration was 28,400&#8201;ng/mL among all samples collected from the actual clinical trial in subjects with HCV, whereas average <italic toggle="yes">C</italic>
<sub>max</sub> at steady&#8208;state in healthy volunteers was only 2350&#8201;ng/mL,<xref rid="psp413023-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> despite of the same dose amount of 150&#8201;mg. This was likely due to decrease in drug clearance in subjects with HCV compared to healthy subjects. Therefore, in the virtual clinical trials, the extent of decrease in hepatic CYP3A4 and OATP1B expression levels in response to each METAVIR fibrosis score were incorporated (Table&#160;<xref rid="psp413023-supitem-0009" ref-type="supplementary-material">S4</xref>). The mRNA levels of CYP3A4 and OATP1B in liver biopsy samples collected from subjects with HCV with METAVIR fibrosis scores of F1, F2, and F3 were measured and found that both mRNA levels were decreasing with progressing the fibrosis state.<xref rid="psp413023-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> For F4 subjects (liver cirrhosis), the reported CYP3A4 and OATP1B protein abundances in liver biopsy samples collected from subjects with cirrhotic liver were incorporated.<xref rid="psp413023-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> In this proteomics study, protein abundances of CYP3A4 and OATP1B were evaluated in patients with Child&#8208;Pugh classes A, B, and C. Because the efficacy and safety study of simeprevir has not been conducted in HCV&#8208;infected patients with Child&#8208;Pugh class B and C,<xref rid="psp413023-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> the reported values from subjects with Child&#8208;Pugh class A were used. Because variabilities in CYP3A4 and OATP1B were not statistically significant among all METAVIR fibrosis scores from F1 to F4, the observed average CV% was used in simulations. In addition, interindividual variability of the CP&#8208;I renal clearance was also considered and assumed that the variability in subjects with HCV was comparable to that in healthy subjects.<xref rid="psp413023-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The results of a total of six virtual clinical trials when the <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> was set at the value estimated by the DDI analysis with atorvastatin (0.00347&#8201;&#956;M) are shown in Figure&#160;<xref rid="psp413023-fig-0005" ref-type="fig">5</xref>. In the actual clinical trial, blood CP&#8208;I concentration increased when blood simeprevir concentrations exceed 2000&#8201;ng/mL (2.67&#8201;&#956;M), and maximum CP&#8208;I concentration reached around 6&#8201;nM. Comparable relationships between simeprevir and CP&#8208;I blood levels were successfully predicted in all virtual clinical trials relative to the actual clinical trial, despite that no parameter optimization to match observed data was conducted. Our simulations showed that blood concentrations of both substances tended to be higher in subjects with severe hepatic impairment (F3 and F4), due to low drug clearances and potent OATP1B inhibition by simeprevir. These simulations clearly demonstrated that PBPK model analysis coupled with Monte Carlo simulation to consider the interindividual variability in drug metabolizing enzymes and transporters was a useful approach to describing and understanding complex DDI cases.</p><p>Simeprevir showed the inhibitory potency against multidrug resistance&#8208;associated protein 2 (MRP2) with the IC<sub>50</sub> of 6.4&#8201;&#956;M (4800&#8201;ng/mL) in vitro.<xref rid="psp413023-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> CP&#8208;I was a substrate of MRP2 as well as OATP1B.<xref rid="psp413023-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Therefore, MRP2 inhibition by simeprevir might be involved in the increase in CP&#8208;I blood levels. However, simulated unbound simeprevir <italic toggle="yes">C</italic>
<sub>max</sub> in hepatocytes (~30&#8201;ng/mL) was much lower than the nominal IC<sub>50</sub>, suggesting that the MRP2 inhibition by simeprevir may not contribute to the interaction between simeprevir and CP&#8208;I. In fact, if the <italic toggle="yes">K</italic>
<sub>i,MRP2</sub> value were set at 1000&#8208;fold lower than the nominal IC<sub>50</sub>, the minimal impact on blood CP&#8208;I concentration was simulated using constructed PBPK models (data not shown).</p><p>In conclusion, in vivo <italic toggle="yes">K</italic>
<sub>i,CYP3A4</sub> and <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> were estimated sequentially by the PBPK modeling approach using DDI cases with midazolam and atorvastatin in healthy subjects. Then, optimized <italic toggle="yes">K</italic>
<sub>i,OATP1B</sub> was verified in the interaction with CP&#8208;I by PBPK model analysis coupled with Monte Carlo simulation to incorporate the interindividual variability in hepatic CYP3A4 and OATP1B expression levels in subjects with HCV in this study. This study has demonstrated that PBPK model analysis can reasonably describe the drug&#8211;drug and &#8208;endogenous biomarker interactions even when the drug&#8208;disease interactions are also involved in the study outcomes.</p></sec><sec id="psp413023-sec-0016"><title>AUTHOR CONTRIBUTIONS</title><p>S.N., K.T., S.Y., J.S., and Y.S. wrote the manuscript. S.N., K.T., and Y.S. designed the research. S.N., K.T., and Y.S. performed the research. S.N., and Y.S. analyzed the data.</p></sec><sec id="psp413023-sec-0018"><title>FUNDING INFORMATION</title><p>No funding was received for this work.</p></sec><sec sec-type="COI-statement" id="psp413023-sec-0019"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declared no competing interests for this work.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp413023-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1</bold> Model code of atorvastatin in Phoenix WinNonLin</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s009.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s007.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S2
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s008.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S3
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S4
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S2
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s004.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0008" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S3
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s006.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0009" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S4
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s010.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="psp413023-supitem-0010" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S5
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-12-1461-s005.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="psp413023-sec-0017"><title>ACKNOWLEDGMENTS</title><p>The authors thank Takashi Yoshikado (Yokohama University of Pharmacy) and Ryuta Asaumi (Astellas Pharma Inc.) for providing model code.</p></ack><ref-list content-type="cited-references" id="psp413023-bibl-0001"><title>REFERENCES</title><ref id="psp413023-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="psp413023-cit-0001"><string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Beumont</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Monshouwer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ouwerkerk&#8208;Mahadevan</surname><given-names>S</given-names></string-name>. <article-title>Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: a PBPK&#8208;guided drug development approach</article-title>. <source>Clin Pharmacol Ther.</source><year>2016</year>;<volume>99</volume>(<issue>2</issue>):<fpage>224</fpage>&#8208;<lpage>234</lpage>.<pub-id pub-id-type="pmid">26259716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.206</pub-id></mixed-citation></ref><ref id="psp413023-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="psp413023-cit-0002"><string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Beumont</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Monshouwer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ouwerkerk&#8208;Mahadevan</surname><given-names>S</given-names></string-name>. <article-title>Elucidating the plasma and liver pharmacokinetics of simeprevir in special populations using physiologically based pharmacokinetic modelling</article-title>. <source>Clin Pharmacokinet.</source><year>2017</year>;<volume>56</volume>(<issue>7</issue>):<fpage>781</fpage>&#8208;<lpage>792</lpage>.<pub-id pub-id-type="pmid">27896690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-016-0476-2</pub-id></mixed-citation></ref><ref id="psp413023-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="psp413023-cit-0003"><string-name name-style="western"><surname>Ouwerkerk&#8208;Mahadevan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Simion</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scheers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Beumont</surname><given-names>M</given-names></string-name>. <article-title>A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers. <italic toggle="yes">Presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy</italic>
</article-title>. <year>2014</year>.</mixed-citation></ref><ref id="psp413023-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="psp413023-cit-0004"><string-name name-style="western"><surname>Yoshikado</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Maeda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Furihata</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Quantitative analyses of the influence of parameters governing rate&#8208;determining process of hepatic elimination of drugs on the magnitudes of drug&#8211;drug interactions via hepatic OATPs and CYP3A using physiologically based pharmacokinetic models</article-title>. <source>J Pharm Sci.</source><year>2017</year>;<volume>106</volume>(<issue>9</issue>):<fpage>2739</fpage>&#8208;<lpage>2750</lpage>.<pub-id pub-id-type="pmid">28495568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2017.05.001</pub-id></mixed-citation></ref><ref id="psp413023-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="psp413023-cit-0005"><string-name name-style="western"><surname>Ouwerkerk&#8208;Mahadevan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peeters</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beumont&#8208;Mauviel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Simion</surname><given-names>A</given-names></string-name>. <article-title>Drug&#8211;drug interactions with the NS3/4A protease inhibitor Simeprevir</article-title>. <source>Clin Pharmacokinet.</source><year>2016</year>;<volume>55</volume>(<issue>2</issue>):<fpage>197</fpage>&#8208;<lpage>208</lpage>.<pub-id pub-id-type="pmid">26353895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0314-y</pub-id><pub-id pub-id-type="pmcid">PMC4756048</pub-id></mixed-citation></ref><ref id="psp413023-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp413023-cit-0006"><string-name name-style="western"><surname>Forns</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lawitz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></string-name>, et al. <article-title>Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial</article-title>. <source>Gastroenterology.</source><year>2014</year>;<volume>146</volume>(<issue>7</issue>):<fpage>1669</fpage>&#8208;<lpage>1679</lpage>.<pub-id pub-id-type="pmid">24602923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.02.051</pub-id></mixed-citation></ref><ref id="psp413023-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp413023-cit-0007"><string-name name-style="western"><surname>Kunze</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ediage</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Dillen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Monshouwer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>. <article-title>Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B&#8208;mediated drug&#8211;drug interactions</article-title>. <source>Clin Pharmacokinet.</source><year>2018</year>;<volume>57</volume>(<issue>12</issue>):<fpage>1559</fpage>&#8208;<lpage>1570</lpage>.<pub-id pub-id-type="pmid">29663259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-018-0648-3</pub-id></mixed-citation></ref><ref id="psp413023-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp413023-cit-0008"><string-name name-style="western"><surname>Nakai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hanada</surname><given-names>K</given-names></string-name>, et al. <article-title>Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+&#8722;taurocholate&#8208;cotransporting polypeptide, organic cation transporter 1, and organic anion&#8208;transporting peptide&#8208;C correlates with the progression of liver fibrosis in chronic hepatitis C patients</article-title>. <source>Drug Metab Dispos.</source><year>2008</year>;<volume>36</volume>(<issue>9</issue>):<fpage>1786</fpage>&#8208;<lpage>1793</lpage>.<pub-id pub-id-type="pmid">18515332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.020073</pub-id></mixed-citation></ref><ref id="psp413023-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="psp413023-cit-0009"><string-name name-style="western"><surname>Asaumi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tobe</surname><given-names>Y</given-names></string-name>, et al. <article-title>Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug&#8211;drug interactions: CYP3A/2C9 induction and OATP inhibition effects</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2018</year>;<volume>7</volume>(<issue>3</issue>):<fpage>186</fpage>&#8208;<lpage>196</lpage>.<pub-id pub-id-type="pmid">29368402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12275</pub-id><pub-id pub-id-type="pmcid">PMC5869557</pub-id></mixed-citation></ref><ref id="psp413023-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="psp413023-cit-0010"><string-name name-style="western"><surname>Asaumi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Menzel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W</given-names></string-name>, et al. <article-title>Expanded physiologically&#8208;based pharmacokinetic model of rifampicin for predicting interactions with drugs and an endogenous biomarker via complex mechanisms including organic anion transporting polypeptide 1B induction</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2019</year>;<volume>8</volume>(<issue>11</issue>):<fpage>845</fpage>&#8208;<lpage>857</lpage>.<pub-id pub-id-type="pmid">31420941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12457</pub-id><pub-id pub-id-type="pmcid">PMC6875706</pub-id></mixed-citation></ref><ref id="psp413023-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="psp413023-cit-0011"><string-name name-style="western"><surname>Asaumi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nunoya</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Yamaura</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Taskar</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Robust physiologically based pharmacokinetic model of rifampicin for predicting drug&#8211;drug interactions via P&#8208;glycoprotein induction and inhibition in the intestine, liver, and kidney</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2022</year>;<volume>11</volume>(<issue>7</issue>):<fpage>919</fpage>&#8208;<lpage>933</lpage>.<pub-id pub-id-type="pmid">35570332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12807</pub-id><pub-id pub-id-type="pmcid">PMC9286720</pub-id></mixed-citation></ref><ref id="psp413023-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="psp413023-cit-0012"><string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Yoshikado</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Quantitative analysis of complex drug&#8211;drug interactions between cerivastatin and metabolism/transport inhibitors using physiologically based pharmacokinetic modeling</article-title>. <source>Drug Metab Dispos.</source><year>2018</year>;<volume>46</volume>(<issue>7</issue>):<fpage>924</fpage>&#8208;<lpage>933</lpage>.<pub-id pub-id-type="pmid">29712725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.117.079210</pub-id></mixed-citation></ref><ref id="psp413023-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="psp413023-cit-0013"><string-name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yoshikado</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Quantitative analysis of complex drug&#8211;drug interactions between repaglinide and cyclosporin a/gemfibrozil using physiologically based pharmacokinetic models with In vitro transporter/enzyme inhibition data</article-title>. <source>J Pharm Sci.</source><year>2017</year>;<volume>106</volume>(<issue>9</issue>):<fpage>2715</fpage>&#8208;<lpage>2726</lpage>.<pub-id pub-id-type="pmid">28479356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2017.04.063</pub-id></mixed-citation></ref><ref id="psp413023-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp413023-cit-0014"><string-name name-style="western"><surname>Nishiyama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ishiguro</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bister</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Physiologically&#8208;based pharmacokinetic Modeling analysis for quantitative prediction of renal transporter&#8208;mediated interactions between metformin and cimetidine</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2019</year>;<volume>8</volume>(<issue>6</issue>):<fpage>396</fpage>&#8208;<lpage>406</lpage>.<pub-id pub-id-type="pmid">30821133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12398</pub-id><pub-id pub-id-type="pmcid">PMC6617824</pub-id></mixed-citation></ref><ref id="psp413023-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp413023-cit-0015"><string-name name-style="western"><surname>Hisaka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ohno</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></string-name>. <article-title>Prediction of pharmacokinetic drug&#8211;drug interaction caused by changes in cytochrome P450 activity using in vivo information</article-title>. <source>Pharmacol Ther.</source><year>2010</year>;<volume>125</volume>(<issue>2</issue>):<fpage>230</fpage>&#8208;<lpage>248</lpage>.<pub-id pub-id-type="pmid">19951720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2009.10.011</pub-id></mixed-citation></ref><ref id="psp413023-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="psp413023-cit-0016"><string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tomaru</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hosokawa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Virtual clinical studies to examine the probability distribution of the AUC at target tissues using physiologically&#8208;based pharmacokinetic modeling: application to analyses of the effect of genetic polymorphism of enzymes and transporters on irinotecan induced side effects</article-title>. <source>Pharm Res.</source><year>2017</year>;<volume>34</volume>(<issue>8</issue>):<fpage>1584</fpage>&#8208;<lpage>1600</lpage>.<pub-id pub-id-type="pmid">28397089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-017-2153-z</pub-id><pub-id pub-id-type="pmcid">PMC5498655</pub-id></mixed-citation></ref><ref id="psp413023-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp413023-cit-0017"><string-name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Maeda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shitara</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Physiologically based pharmacokinetic modeling to predict transporter&#8208;mediated clearance and distribution of pravastatin in humans</article-title>. <source>J Pharmacol Exp Ther.</source><year>2009</year>;<volume>328</volume>(<issue>2</issue>):<fpage>652</fpage>&#8208;<lpage>662</lpage>.<pub-id pub-id-type="pmid">19001154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.108.146647</pub-id></mixed-citation></ref><ref id="psp413023-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp413023-cit-0018"><string-name name-style="western"><surname>Cong</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Doherty</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>KS</given-names></string-name>. <article-title>A new physiologically based, segregated&#8208;flow model to explain route&#8208;dependent intestinal metabolism</article-title>. <source>Drug Metab Dispos.</source><year>2000</year>;<volume>28</volume>(<issue>2</issue>):<fpage>224</fpage>&#8208;<lpage>235</lpage>.<pub-id pub-id-type="pmid">10640522</pub-id></mixed-citation></ref><ref id="psp413023-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="psp413023-cit-0019"><string-name name-style="western"><surname>Rodgers</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Leahy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rowland</surname><given-names>M</given-names></string-name>. <article-title>Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate&#8208;to&#8208;strong bases</article-title>. <source>J Pharm Sci.</source><year>2005</year>;<volume>94</volume>(<issue>6</issue>):<fpage>1259</fpage>&#8208;<lpage>1276</lpage>.<pub-id pub-id-type="pmid">15858854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.20322</pub-id></mixed-citation></ref><ref id="psp413023-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="psp413023-cit-0020"><string-name name-style="western"><surname>Rodgers</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rowland</surname><given-names>M</given-names></string-name>. <article-title>Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions</article-title>. <source>J Pharm Sci.</source><year>2006</year>;<volume>95</volume>(<issue>6</issue>):<fpage>1238</fpage>&#8208;<lpage>1257</lpage>.<pub-id pub-id-type="pmid">16639716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.20502</pub-id></mixed-citation></ref><ref id="psp413023-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="psp413023-cit-0021"><collab collab-type="authors">Center for Drug Evaluation and Research, FDA</collab>
. <article-title>Pharmacology Review(s)</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000PharmR.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000PharmR.pdf</ext-link></mixed-citation></ref><ref id="psp413023-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="psp413023-cit-0022"><string-name name-style="western"><surname>Yoshikado</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Maeda</surname><given-names>K</given-names></string-name>, et al. <article-title>PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2018</year>;<volume>7</volume>(<issue>11</issue>):<fpage>739</fpage>&#8208;<lpage>747</lpage>.<pub-id pub-id-type="pmid">30175555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12348</pub-id><pub-id pub-id-type="pmcid">PMC6263667</pub-id></mixed-citation></ref><ref id="psp413023-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="psp413023-cit-0023"><string-name name-style="western"><surname>Lennern&#228;s</surname><given-names>H</given-names></string-name>. <article-title>Clinical pharmacokinetics of atorvastatin</article-title>. <source>Clin Pharmacokinet.</source><year>2003</year>;<volume>42</volume>(<issue>13</issue>):<fpage>1141</fpage>&#8208;<lpage>1160</lpage>.<pub-id pub-id-type="pmid">14531725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200342130-00005</pub-id></mixed-citation></ref><ref id="psp413023-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="psp413023-cit-0024"><string-name name-style="western"><surname>Yoshikado</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Aoki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mochizuki</surname><given-names>T</given-names></string-name>, et al. <article-title>Cluster Gauss&#8208;Newton method analyses of PBPK model parameter combinations of coproporphyrin&#8208;I based on OATP1B&#8208;mediated rifampicin interaction studies</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2022</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1341</fpage>&#8208;<lpage>1357</lpage>.<pub-id pub-id-type="pmid">35945914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12849</pub-id><pub-id pub-id-type="pmcid">PMC9574750</pub-id></mixed-citation></ref><ref id="psp413023-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="psp413023-cit-0025"><string-name name-style="western"><surname>Feng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname><given-names>HA</given-names></string-name>, et al. <article-title>Evaluation of coproporphyrins as clinical endogenous markers for OATP1B</article-title>. <source>J Clin Pharmacol.</source><year>2021</year>;<volume>61</volume>(<issue>8</issue>):<fpage>1027</fpage>&#8208;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">33460165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1817</pub-id></mixed-citation></ref><ref id="psp413023-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp413023-cit-0026"><string-name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Imamura</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Tanigawara</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Application of PBPK modeling and virtual clinical study approaches to predict the outcomes of CYP2D6 genotype&#8208;guided dosing of tamoxifen</article-title>. <source>CPT Pharmacometrics Syst Pharmacol.</source><year>2018</year>;<volume>7</volume>(<issue>7</issue>):<fpage>474</fpage>&#8208;<lpage>482</lpage>.<pub-id pub-id-type="pmid">29920987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12307</pub-id><pub-id pub-id-type="pmcid">PMC6063740</pub-id></mixed-citation></ref><ref id="psp413023-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="psp413023-cit-0027"><string-name name-style="western"><surname>El&#8208;Khateeb</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Achour</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Majdoub</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rostami&#8208;Hodjegan</surname><given-names>A</given-names></string-name>. <article-title>Non&#8208;uniformity of changes in drug&#8208;metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment</article-title>. <source>Mol Pharm.</source><year>2021</year>;<volume>18</volume>(<issue>9</issue>):<fpage>3563</fpage>&#8208;<lpage>3577</lpage>.<pub-id pub-id-type="pmid">34428046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.1c00462</pub-id><pub-id pub-id-type="pmcid">PMC8424631</pub-id></mixed-citation></ref><ref id="psp413023-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="psp413023-cit-0028"><string-name name-style="western"><surname>Toshimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fukuchi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Aoki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></string-name>. <article-title>Middle&#8208;out approach for PBPK modeling using cluster Gauss&#8208;Newton method: application to the nonlinear pharmacokinetics analysis of simeprevir. <italic toggle="yes">Presented at the 36th Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX)</italic>
</article-title>. <year>2021</year>.</mixed-citation></ref><ref id="psp413023-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="psp413023-cit-0029"><collab collab-type="authors">Center for Drug Evaluation and Research, FDA</collab>
. <article-title>Prescribing Information</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf</ext-link></mixed-citation></ref><ref id="psp413023-bib-0030"><label>30</label><mixed-citation publication-type="miscellaneous" id="psp413023-cit-0030"><string-name name-style="western"><surname>Huisman</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Snoeys</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Monbaliu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Martens</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sekar</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Raoof</surname><given-names>A</given-names></string-name>. <article-title>In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. <italic toggle="yes">Presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD)</italic>
</article-title>. <year>2010</year>.</mixed-citation></ref><ref id="psp413023-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="psp413023-cit-0031"><string-name name-style="western"><surname>Ring</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Chien</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Adkison</surname><given-names>KK</given-names></string-name>, et al. <article-title>PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance</article-title>. <source>J Pharm Sci.</source><year>2011</year>;<volume>100</volume>(<issue>10</issue>):<fpage>4090</fpage>&#8208;<lpage>4110</lpage>.<pub-id pub-id-type="pmid">21541938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.22552</pub-id></mixed-citation></ref><ref id="psp413023-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="psp413023-cit-0032"><collab collab-type="authors">Center for Drug Evaluation and Research, FDA</collab>
. <article-title>In vitro drug interaction studies &#8211; cytochrome P450 enzyme&#8208; and transporter&#8208;mediated drug interactions guidance for industry</article-title>. <year>2020</year>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>